Correction to: Scientific Reports 10.1038/s41598-017-01160-1, published online 21 April 2017
This Article contains errors in the first column of Table 1, where the reference numbers are incorrect. All these articles are already referenced in the Article, and the Table with the corrected reference numbers is included below.
Table 1.
The characteristics of included studies. CHD Coronary heart disease; DM diabetes mellitus; CAG coronary angiography; PCI percutaneous coronary intervention; PAG peripheral angiography; PTA percutaneous transluminal angioplasty; CECT contrast-enhanced computerised tomography; M male; F female; NS normal saline; d day; h hour; min minute; iv intravenous injection.
| First author | Publication year | Sample size | Age (years) | Object of study | NO. of CIN (case/control) | Observation index | Experimental group treatment strategy(alprostadil) | Jadad score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case(M/F) | Control(M/F) | Case | Control | BUN | CysC | Scr | ||||||
| Franz RW[11] | 2011 | 20(12/8) | 21(17/4) | 48–87 | 48–87 | vascular surgery | 0/1 | oral 200 μg preoperative | 4 | |||
| Li B[24] | 2011 | 34(34/0) | 26(26/0) | 69.4 ± 7.3 | 67.9 ± 6.8 | CHD CAG/PCI | 2/3 | 48 h | 48 h | 20 μg + NS 20 ml iv qd, 30 min preoperative, continue 3d postoperative | 2 | |
| Li JZ[25] | 2016 | 50(33/17) | 53(34/19) | 58.11 ± 9.7 | 56.84 ± 9.29 | CHD PCI | 1/6 | 24 h,72 h | 10 μg + NS 100 ml iv drip qd, 1d preoperative, 3d postoperative | 2 | ||
| Liu H[26] | 2013 | 30(16/14) | 30(15/15) | 55–74 | 55–75 | DM PAG | 0/0 | 24 h,48 h | 24 h,48 h | 10 μg + NS 10 ml iv qd, 3d preoperative | 3 | |
| Liu Y[27] | 2011 | 29(16/13) | 29(19/10) | 57.0 ± 7.5 | 59.4 ± 9.2 | CHD CAG/PCI | 4/13 | 48 h,72 h | 48 h,72 h | 10 μg + NS 50 ml iv pumping bid, 7d postoperative | 2 | |
| Liu YY[28] | 2011 | 82(51/31) | 84(51/33) | 60.8 ± 12.5 | 61.7 ± 12.8 | CHD CAG/PCI | 2/3 | 48 h | 20 ng/kg/min, continue 6 h postoperative | 2 | ||
| Li XY[29] | 2013 | 14(8/6) | 15(11/4) | 66 ± 12 | 66 ± 12 | DM PAG or PTA | 0/2 | 24 h,72 h | 24 h,72 h | 2 ng/kg/min, continue 6 h preoperative and 20 μg + NS 40 ml iv qd, the second day, 5d postoperative | 3 | |
| Li YN[30] | 2014 | 150(96/54) | 150(54/96) | 68.02 ± 7.03 | 68.49 ± 6.10 | CHD CAG/PCI | 4/13 | 72 h | 72 h | 10 μg + NS 100 ml iv drip qd, 0.5-1 h preoperative, 3d postoperative | 3 | |
| Miao Y[31] | 2013 | 154(120/34) | 176(133/43) | 79.08 ± 6.16 | 78.26 ± 6.61 | CECT | 14/39 | 24 h,48 h,72 h | 24 h,48 h,72 h | 0.4 μg/kg/day, 48 h preoperative, continue to 48 h postoperative | 4 | |
| Su C[32] | 2015 | 55(35/20) | 51(33/18) | 62.7 ± 10.8 | 63.5 ± 11.2 | CHD PCI | 2/7 | 72 h | 72 h | 10 μg + NS 100 ml iv drip qd, 1 day preoperative, 3d postoperative | 2 | |
| Wang L[33] | 2016 | 50(31/19) | 50(32/18) | 60.48 ± 4.51 | 60.5 ± 4.17 | CHD CAG/PCI | 2/8 | 72 h | 72 h | 20 μg + NS 40 ml iv drip qd, 30 min preoperative,0.5,1, 2d postoperative | 2 | |
| Wang ZD[34] | 2015 | 65(49/16) | 63(48/15) | 58.2 ± 10.8 | 59.1 ± 11.2 | CHD CAG/PCI | 7/17 | 24 h,48 h,72 h | 24 h,48 h,72 h | 10 μg + NS 20 ml iv qd preoperative, 7d postoperative | 3 | |
| Xu R[35] | 2012 | 30(13/17) | 30(12/18) | 60 ± 9 | 60 ± 11 | CHD CAG/PCI | 2/10 | 24 h,48 h | 10 μg + NS 20 ml iv qd, preoperative, 7d postoperative | 2 | ||
| Yan HY[36] | 2014 | 21(12/9) | 19(11/8) | 73.3 ± 6.3 | 75.1 ± 8.5 | PAG | 4/8 | 24 h,48 h,72 h | 24 h,48 h,72 h | 24 h,48 h,72 h | 10 μg + NS 10 ml iv bid, 3d postoperative | 2 |
| Ye Y[37] | 2006 | 28(25/3) | 30(26/4) | 70.28 ± 5.6 | 72.62 ± 9.15 | PAG/CECT | 6/14 | 48 h,72 h | 48 h,72 h | 20 μg + NS 20 ml iv, qd, 3d postoperative | 2 | |
| Zhao HW[38] | 2014 | 58(31/27) | 58(39/19) | 64 ± 9 | 65 ± 8 | CHD DM PCI | 2/9 | 72 h | 72 h | 10 μg + NS 100 ml iv drip qd, 1d preoperative, 4d postoperative | 2 | |
| Zhong SG[39] | 2014 | 50(38/12) | 50(39/11) | 63.9 ± 7.6 | 64.1 ± 8.0 | CHD DM PCI | 1/8 | 72 h | 72 h | 100 μg + NS 100 ml iv drip bid, 3d postoperative | 2 | |
| Zhou DC[40] | 2013 | 112(65) | 103(61) | 62.1 ± 11.1 | 63.2 ± 10.9 | CHD CAG/PCI | 8/19 | 10 μg + NS 10 ml iv bid, 1d postoperative, 7-10d postoperative | 3 | |||
| Zhu L[41] | 2011 | 99(99/0) | 98(98/0) | 57 ± 15 | 57 ± 15 | CHD CAG ± PCI | 7/19 | 48 h | 48 h | 48 h | 20 μg + NS 20 ml iv qd, 10d postoperative | 2 |
In addition, Table 1 contains an error in the ‘Experimental group treatment strategy(alprostadil)’ for the study by Franz RW [11] where,
“oral 200 mg preoperative”
should read:
“oral 200 μg preoperative”